The path to successful gene-modified cell therapy starts long before commercialization. Join us September 8 to learn how aligning plasmid design, critical materials, and cGMP manufacturing can help support more consistent, scalable outcomes throughout development, including:

• How early plasmid design decisions influence downstream performance
• ️Strategies to improve reproducibility and reduce variability
• Key considerations for scaling from development to commercialization
• Where disconnects commonly occur, and how to build a more connected workflow